RxDoctor Payments Data

Kathryn Moore, APRN

Family · Raleigh, NCNPI 1750553178

Payments from drug & device makers

$5,084in general payments, 2019–2025

Across 260 payments — averaging $19.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Gilead$1K
  • Johnson & Johnson$552
  • Merck$380
  • Janssen Products, LP$166
  • AbbVie$102
  • plus $134 from 3 others

What the payments were for

  • Food & beverage$4,90797%
  • Education$1773%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,084 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$6,976
Medicare patients
23
Services billed
129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala343$1,418,680
TivicayDolutegravir Sodium143$345,856
DescovyEmtricitabine/Tenofov Alafenam145$323,837
DovatoDolutegravir Sodium/Lamivudine72$229,005
JulucaDolutegravir/Rilpivirine29$104,955
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf20$100,003
TriumeqAbacavir/Dolutegravir/Lamivudi19$79,123
OdefseyEmtricitab/Rilpiviri/Tenof Ala13$54,608
IsentressRaltegravir Potassium12$25,198
TrulicityDulaglutide20$19,526
JardianceEmpagliflozin29$17,961
OzempicSemaglutide17$16,533
FarxigaDapagliflozin Propanediol17$10,831
NeuproRotigotine11$9,326
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,480

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$1,283$1,742,517488 claims
Viiv Healthcare CompanyTivicay, Dovato, Juluca, Triumeq$2,468$758,940263 claims
Janssen Products, LPSymtuza$166$100,00320 claims
MerckIsentress$380$25,19812 claims
Johnson & JohnsonXarelto$552$6,30511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.

Other family in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →